Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies

ABSTRACT:

SUBMITTER: Finn R 

PROVIDER: S-EPMC12143813 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature